BridGene Biosciences, a pioneer in developing small molecule drugs targeting traditionally difficult proteins, has successfully closed a $28 million Series B+ funding round. The financing was led by Bayland Capital and included contributions from GTJA Investment Group, Proxima Ventures, as well as existing backers Lapam Capital and Grains Valley Venture Capital.
Health Technology Insights: Myriad and SOPHiA Partner on Liquid Biopsy Diagnostic Tool
The new capital will primarily support the continued clinical advancement of BGC-515, BridGene’s covalent TEAD inhibitor aimed at treating solid tumors, as it moves toward Phase 2 trials. In addition to this, the funds will accelerate progress on the company’s second program, which is planned to enter clinical testing in 2027. BridGene also intends to use the proceeds to boost the development of further oncology and autoimmune candidates. This round will enable the company to deepen strategic partnerships and validate the wide-ranging potential of its proprietary IMTAC chemoproteomic platform, which is designed to identify novel drug targets across cancer, immune-related disorders, and neurological conditions.
Health Technology Insights: Ultromics Study Shows AI Could Improve Early Detection of Cardiac Amyloidosis
Ping Cao, Ph.D., CEO and co-founder of BridGene Biosciences, explained that this financing is a critical step to support the advancement of their lead candidate BGC-515 through Phase 2 clinical trials. Cao emphasized that the funding will also help move additional pipeline projects toward clinical evaluation while expanding the company’s platform capabilities through new collaborations. The goal is to continue turning innovative scientific discoveries into meaningful therapies for patients.
Yuexing Su, founding partner at Bayland Capital, expressed strong enthusiasm for leading the investment round. Su highlighted BridGene’s IMTAC platform as a unique and powerful tool that enables the discovery of small molecule drugs against targets that have traditionally been difficult to address with conventional methods. With a growing portfolio centered on BGC-515 and several other promising programs in oncology and autoimmune diseases, Su believes BridGene is well positioned to deliver breakthrough treatments and create significant value in the biotech industry.
Health Technology Insights: Sidecar Health Partners with Carrum Health for Centers of Excellence
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
